MétaCan
Menu
← Back to cohort

Bimodality versus trimodality therapy for locally advanced non-small cell lung cancer (NSCLC) at the British Columbia Cancer Agency: Favorable outcomes and low treatment-related mortality with multidisciplinary patient selection

2005· article· en· W2399551246 on OpenAlexaffabout
Sijin Sun, Finbarr Sheehan, Katrina A.B. Goddard, B. Melosky, Rebecca S. Finley, C. Grafton, Kenneth G. Evans, Nevin Murray

Bibliographic record

VenueJournal of Clinical Oncology · 2005
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsMedicineRadiation therapySurgeryCancerRetrospective cohort studyLung cancerInduction chemotherapyStage (stratigraphy)Performance statusChemotherapyInternal medicine

Abstract

fetched live from OpenAlex

7233 Background: The benefit of surgical resection after induction chemoradiation for locally advanced NSCLC is controversial. The purpose of this retrospective study was to examine the feasibility, safety and efficacy of combined modality therapy. Methods: Between 1998 and 2004, 68 patients with stage IIB (n=2) and III (n=66) NSCLC, median age 57, good performance status and minimal weight loss were selected by a multidisciplinary team. 20 patients were inoperable at diagnosis and received concurrent chemoradiation alone. 48 patients received chemoradiation, followed by surgery if feasible. 25/48 patients were candidates for surgery after their induction chemoradiation. 1 patient refused surgery and 3 patients were inoperable at thoracotomy. Results: In total, 43 patients received concurrent chemoradiation alone (18 received higher dose 50–61Gy radiation and 25 received 40–45Gy). The median survival for all bimodality patients was 21 months with a 4-year survival of 28%. Patients receiving a higher dose of radiation had a median survival of 24 months and a 4-year survival of 48% as compared to 17 months and 16% for patients receiving lower dose radiation. For trimodality patients, the median survival was 47 months with a 4-year survival of 44%. 20/21 (95%) of patients who underwent resection had pathologic downstaging of their tumor (6 patients with no residual disease). There were no treatment-related deaths. Conclusions: Combined modality therapy is safe and feasible in selected patients. Bimodality patients receiving higher dose radiotherapy appeared to have a longer median survival and higher 4 year survival rate. The observed pathologic complete response rate (29%) was similar to previous reports. The favorable results seen with the trimodality approach reflect careful multidisciplinary patient selection. No significant financial relationships to disclose.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Direct model labels (unvalidated)

Per-model category and study-design labels from the labeling rounds. They are machine output, unvalidated, and the disagreement between models ships as data. No study design here is MEDLINE-validated yet.

Model armCategoriesStudy designConfidence
gemmano category
Domain: not available · Genre: Empirical
About the Canadian research system: yes · About a Canadian topic: no
Observationallow
gptno category
Domain: not available · Genre: Empirical
About the Canadian research system: no · About a Canadian topic: no
Observationallow
models agreeAgreement compares identical category sets and study designs across arms.

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.045
GPT teacher head0.439
Teacher spread0.394 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Labeled directly by 2 models reading the full record.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2005
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicLung Cancer Treatments and Mutations→French-language works237,207→